Lilly anti-inflammatory drug might shorten COVID-19 recovery time

Indianapolis-based Eli Lilly and Co. says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day.

Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The result have not yet been published or reviewed by independent scientists.

Lilly shares rose about 1% in midday trading, to $149.48 each.

The study tested baricitinib, a pill that Lilly already sells as Olumiant to treat rheumatoid arthritis, the less common form of arthritis that occurs when a mistaken or overreacting immune system attacks joints, causing inflammation. An overactive immune system also can lead to serious problems in coronavirus patients.

All study participants received remdesivir, a Gilead Sciences drug previously shown to reduce the time to recovery, defined as being well enough to leave the hospital, by four days on average. Those who also were given baricitinib recovered one day sooner than those given remdesivir alone, Lilly said.

Lilly said it planned to discuss with regulators the possible emergency use of baricitinib for hospitalized COVID-19 patients.

It would be important to know how many study participants also received steroid drugs, which have been shown in other research to lower the risk of death for severely ill, hospitalized COVID-19 patients, said Dr. Jesse Goodman, former U.S. Food and Drug Administration chief scientist now at Georgetown University who had no role in the study.

Figuring out how to best use the various drugs shown to help “is something we’re going to have to work at,” he said.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

2 thoughts on “Lilly anti-inflammatory drug might shorten COVID-19 recovery time

  1. You mean like Hydroxycloroquine? I sure hope our president doesn’t endorse his product. Then IBJ and the rest of the media will have to disavow it
    as quackery. IBJ throws in anti inflammatory and Lily just make the masses that it’s something new.

    Not gonna buy it IBJ.

  2. Thats just Awesome!
    BUT

    Why have anything downtown Our highways are full of trash and debris. You cannot even use the Emerngcy lanes. I went to Detroit yesterday and the the highways were so clean through the city every Direction.
    Our Mayer is trying to destroy Indpls.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}